



FOR IMMEDIATE RELEASE

RoverMed BioSciences Announces New Findings at Keystone Symposium

New data presents a potentially significant advance in the field of CRISPR therapeutics.

St. Paul, MN (February 9, 2018) RoverMed BioSciences, a leader in non-viral formulation and delivery of RNA, DNA and protein therapies, reported exciting results at the Keystone Symposium in Keystone, CO.

RoverMed's data related to intravenous targeted delivery of CRISPR ribonucleoprotein (RNP) complexes using RoverMed's proprietary Crystalline Ultra-Small nanoParticles (CUSP) highlights a potentially significant advance in the field of CRISPR therapeutics. RoverMed's findings show the potential of CUSP technology to overcome RNP-related toxicity barriers, and demonstrate the successful delivery of RNP complexes intact to target cells for safe and effective treatment *in vivo*. The results were presented at the Keystone Symposium for Precision Genome Editing with Programmable Nucleases in Keystone, CO (www.keystone.symposia.org/18B1)

"CUSP's successful delivery of the bacterial Cas9 protein with sgRNA using clinically-relevant, low volume intravenous protocols with repeat dosing potentially marks a significant advance in the field of CRISPR therapies," said Gretchen Unger, Ph.D., Chief Scientific Officer of RoverMed. "With the results reported at Keystone and the mechanistic insights we continue to accrue, RoverMed is looking forward to continuing development with our multiple current and prospective partners."

"The intrinsic value of our company is our continued commitment to breakthrough science," said Laura Brod, CEO RoverMed. "Dr. Unger and her team do the tireless work every day to achieve results for our partners and ultimately improve the quality of life for patients undergoing treatment with gene and pharmaceutical therapies."

About RoverMed BioSciences

RoverMed is developing novel, targeted, drug delivery technology to enable new classes of therapeutics. The company's CUSP technology provides drug-loaded particles of unique structure and 20-nanometer size for targeted delivery of RNA, DNA, and protein therapies. CUSP's unique design exploits important delivery mechanisms that collectively avoid triggering inflammatory responses, which typically degrade macromolecule therapies. RoverMed is currently working with several drug developers at different stages of pre-clinical work to create advanced new therapies incorporating CUSP technology.

Media Contact: Jing Zhang
Media Email: jing@ainsleyshea.com
Media Phone: 651-414-1095
www.rovermed.com